Skip to content

Krystal Biotech

US · KRYS #1515 by market cap Listed 2017
308.89 -6.93 -2.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 20 in the most recent period (2026/Q3).
  • Total institutional ownership fell 1.9 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
100.46% -1.92pp
Institutions
535 +20
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund74.57%
Hedge Fund17.36%
Individual/Insider9.93%
Public Company2.89%
VC/PE Fund2.15%
Private Company1.18%
Sovereign Wealth Fund0.89%
Government Pension Fund0.82%
Insurance Company0.35%

Top holders as of 2026-09-30

FMR 14.98% · 4.44M sh
BlackRock 12.12% · 3.59M sh
Avoro Capital Advisors LLC 9.75% · 2.89M sh
Suma Krishnan 4.87% · 1.44M sh
Krish Krishnan 4.81% · 1.43M sh
State Street Global Advisors 4.79% · 1.42M sh
Vanguard Portfolio Management, LLC 4.34% · 1.29M sh
Vanguard Capital Management, LLC 4.04% · 1.20M sh
Soleus Capital Management, L.P. 3.17% · 939.25K sh
Capital Research 2.63% · 777.84K sh
Geode Capital Management, LLC 2.74% · 811.74K sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 19 buys · 25 sells

NameRoleStake
Suma Krishnan Founder, President of R&D and Director 4.87%
Krish Krishnan Chairperson & CEO 4.81%
Dino Rossi Independent Director 0.17%
Kathryn Romano Chief Accounting Officer 0.08%
Laurent Goux Executive VP & Head of International 0.00%
Daniel Janney Lead Independent Director --
Julian Gangolli Independent Director --
E. Sutherland Independent Director --
Alta Bioequities -- --
Christopher Mason Independent Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-11 Dino Rossi Independent Director Other Disposition -3,500 --
2026-09-13 Daniel Janney Lead Independent Director Other Derivative Acquisition +471 --
2026-09-13 Daniel Janney Lead Independent Director Other Derivative Acquisition +1,187 $340.03
2026-09-13 Dino Rossi Independent Director Other Derivative Acquisition +471 --
2026-09-13 Dino Rossi Independent Director Other Derivative Acquisition +1,187 $340.03
2026-09-13 Julian Gangolli Independent Director Other Derivative Acquisition +471 --
2026-09-13 Julian Gangolli Independent Director Other Derivative Acquisition +1,187 $340.03
2026-09-13 E. Sutherland Independent Director Other Derivative Acquisition +471 --
2026-09-13 E. Sutherland Independent Director Other Derivative Acquisition +1,187 $340.03
2026-09-13 Christopher Mason Independent Director Other Derivative Acquisition +471 --
2026-09-13 Christopher Mason Independent Director Other Derivative Acquisition +1,187 $340.03
2026-09-13 Catherine Mazzacco Independent Director Other Derivative Acquisition +471 --
2026-09-13 Catherine Mazzacco Independent Director Other Derivative Acquisition +1,187 $340.03
2026-09-03 Krish Krishnan Chairperson & CEO Automatic Disposition -520 $354.54
2026-09-03 Krish Krishnan Chairperson & CEO Open Market Disposition -24,480 $355.57–366.56
2026-09-03 Suma Krishnan Founder, President of R&D and Director Automatic Disposition -520 $354.54
2026-09-03 Suma Krishnan Founder, President of R&D and Director Open Market Disposition -24,480 $355.57–366.56
2026-08-13 Dino Rossi Independent Director Other Disposition -3,691 --
2026-08-13 Dino Rossi Independent Director Open Market Disposition -25,000 $325.60–333.23
2026-06-24 John Thomas EVP, General Counsel & Corporate Secretary Derivative Exercise and Sale -1,000 $179.25–347.27

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Krystal Biotech discussion 0 comments

Add a comment